Literature DB >> 31613694

Right to Try Requests and Oncologists' Gatekeeping Obligations.

Holly Fernandez Lynch1, Ameet Sarpatwari2, Robert H Vonderheide1, Patricia J Zettler3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31613694      PMCID： PMC7032880          DOI： 10.1200/JCO.19.01741

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  The terminally ill, access to investigational drugs, and FDA rules.

Authors:  Valarie Blake
Journal:  Virtual Mentor       Date:  2013-08-01

2.  Promoting Patient Interests in Implementing the Federal Right to Try Act.

Authors:  Holly Fernandez Lynch; Patricia J Zettler; Ameet Sarpatwari
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

3.  Who Stands to Benefit? Right to Try Law Provisions and Implications.

Authors:  Lisa Kearns; Alison Bateman-House
Journal:  Ther Innov Regul Sci       Date:  2017-03       Impact factor: 1.778

4.  The strange allure of state "right-to-try" laws.

Authors:  Patricia J Zettler; Henry T Greely
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

5.  The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.

Authors:  Alison Bateman-House; Christopher T Robertson
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

6.  Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.

Authors:  Steven Joffe; Holly Fernandez Lynch
Journal:  N Engl J Med       Date:  2018-01-10       Impact factor: 91.245

Review 7.  How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?

Authors:  Amy E McKee; André O Markon; Kirk M Chan-Tack; Peter Lurie
Journal:  J Clin Pharmacol       Date:  2017-10       Impact factor: 3.126

8.  Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.

Authors:  Jonathan P Jarow; Steven Lemery; Kevin Bugin; Naomi Lowy
Journal:  Ther Innov Regul Sci       Date:  2017-03-01       Impact factor: 1.778

9.  Federal Right to Try: Where Is It Going?

Authors:  Kelly Folkers; Carolyn Chapman; Barbara Redman
Journal:  Hastings Cent Rep       Date:  2019-03       Impact factor: 2.683

10.  Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.

Authors:  Gideon M Blumenthal; Richard Pazdur
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675
  10 in total
  3 in total

1.  Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology.

Authors:  David S Shulman; Lulla V Kiwinda; Stacey Edwards; Catherine M Clinton; Sarah Hunt; Lianne Greenspan; Kristen D Lawler; Gregory Reaman; Hasan Al-Sayegh; Kira Bona; Allison F O'Neill; Suzanne Shusterman; Katherine A Janeway; Andrew E Place; Susan N Chi; Clement Ma; Steven G DuBois
Journal:  Cancer Med       Date:  2021-03-09       Impact factor: 4.711

2.  "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.

Authors:  Cambray Smith; Jeremiah Stout; Alex A Adjei; Jan Buckner; Mark Wentworth; Jon Tilburt; Zubin Master
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

3.  Ethics framework for treatment use of investigational drugs.

Authors:  Jan Borysowski; Andrzej Górski
Journal:  BMC Med Ethics       Date:  2020-11-18       Impact factor: 2.652
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.